📰 Anna Juncker Jensen News
Anna Juncker Jensen News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Anna Juncker Jensen. Real-time updates on events, politics, business and more.
July 30, 2023
Most ovarian cancer patients are diagnosed at an advanced stage of the disease. Fewer than one-third of individuals diagnosed survive five years.
July 25, 2023
News, information and events for University of Notre Dame faculty, staff and their families. This is your Notre Dame.
July 24, 2023
As the third most common type of gynecological cancer, ovarian cancer caused more than 200,000 reported deaths globally in 2020 alone
July 23, 2023
Washington, DC: Most ovarian cancer patients are diagnosed at the most advanced stage of the illness. Less than one-third of those who receive a diagnosis
July 21, 2023
A new study links a high body mass index (BMI) to alterations in the structure and environment of ovarian cancer.
July 20, 2023
Most women with ovarian cancer are diagnosed with the most advanced form of the disease. Less than a third of those diagnosed with the disease survive five years later. As the third most common type of gynecological cancer, it led to more than 200,000 reported deaths globally in 2020 alone, according to a recent study.
July 18, 2023
A new study links a high body mass index (BMI) to alterations in the structure and environment of cancerous tumors. Most women with ovarian cancer are d...
September 30, 2022
The expansion is part of the company’s growth strategy for North America and will foster collaboration with life science companies and academiaAn inauguration event will take place on October 12, featuring presentations from collaborators at NeoGenomics, Takeda and KymeraZURICH, Switzerland and CAMBRIDGE, Mass...
September 29, 2022
Investegate announcements from Biognosys AG, Biognosys Expands Its Global Presence with a US Office in Biopharma Hub Cambridge, Massachusetts
March 31, 2022
Data from Biognosys and its collaborators demonstrate the technological advances and utility of their proteomics platforms in oncology R&D and clinical settings Biognosys, a leader in next-generation